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Abstract The ‘‘MS in the 21st Century’’ initiative was
established with the purpose of (1) defining how multiple
sclerosis (MS) treatment and standards of care should look
in the 21st century; (2) developing a minimum standard of
care across the world; and (3) motivating the broad MS
community to align standards of care and challenge the
current treatment paradigm. The aim was to develop a
consensus statement to reach and influence the broader MS
community. An expert steering group from Europe and
Canada—consisting of neurologists, patient advocates, a
pharmacoepidemiologist/pharmacoeconomist, and repre-
sentatives from national MS centers—participated in a
series of workshop-driven meetings between February
2011 and 2012. After three phases of discussions, the
steering group identified that the overall vision for future
care of MS should be full access to personalized treatment,
with reimbursement, to achieve freedom from disease.
They constructed seven overall principles that support this
vision: personalized care, patient engagement, commitment
to research, regulatory body education and reimbursement
issues, new endpoints in clinical trials, more therapy
options, and MS centers of excellence. This consensus
statement outlines the key aspects of the seven principles
that need to be addressed. The ‘‘MS in the 21st Century
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Steering Group’’ hopes that this consensus statement acts
as a call to action for healthcare providers and decision-
makers to address simultaneously the overarching princi-
ples that will guide patient management in order to
improve outcomes for people with MS.
Keywords Multiple sclerosis  Care  Management 
Consensus statement
Introduction
More than 2.5 million people worldwide are estimated to
be affected by multiple sclerosis (MS), with almost
500,000 of them living in the European Union (EU) [1].
Current medications slow the accumulation of disability in
MS and reduce the frequency of relapses by modulating or
(selectively) suppressing the patient’s immune system [2].
Although scientific evidence exists to show that early
access to effective treatment and care is cost-efficient to
society and has a meaningful impact on the quality of life
of patients [3], significant disparity still exists between and
within countries in the standard of treatment offered to
people with MS [4]. There also remains a lack of awareness
and education of MS in general among healthcare profes-
sionals, patients, and the general public [5–8]. In addition,
available treatments have limited efficacy [9].
In February 2011, the MS in the 21st Century initiative
was established with the purpose of (1) defining how MS
treatment and standards of care should look in the 21st
century; (2) developing a minimum standard of care across
the world and; (3) motivating the broad MS community to
align standards of care and challenge the current treatment
paradigm. The project has been run by an independent
agency, iS Health, with the support of an unrestricted
educational grant from Merck Serono.
The aim was to develop a consensus statement to reach
and influence the broader MS community and serve as a
reference tool for stakeholders who can influence the future
care of MS patients.
Methods
Steering group
Candidates for the MS in the 21st Century Steering Group
were identified by iS Health to meet the following criteria:
they should comprise key patient groups and leading clini-
cians active in the treatment and management of MS; and
they should represent different groups in different countries
worldwide.
The steering group comprises the following members:
Peter Rieckmann (Neurologist, Bamberg, Germany);
Alexei Boyko (Neurologist, Moscow, Russia); Diego
Centonze (Neurologist, Rome, Italy); Alasdair Coles
(Neurologist, Cambridge, UK); Irina Elovaara (Neurolo-
gist, Tampere, Finland); Eva Havrdova´ (Neurologist,
Prague, Czech Republic); Otto Hommes (Neurologist,
European Charcot Foundation, Molenhoek (Nijmegen
area), The Netherlands); Jacques LeLorier (Internist Phar-
macoepidemiologist and Pharmacoeconomist, Montreal,
Canada); Sarah A. Morrow (Neurologist, London, Canada);
Celia Oreja-Guevara (Neurologist, Madrid, Spain); Nick
Rijke (Interim Director of Policy and Research, UK MS
Society, London, UK) and Sven Schippling (Neurologist,
Zurich, Switzerland).
Consensus process
Experts in the area of MS care were asked to be members
of the steering committee for the MS in the 21st Century
initiative and were invited to participate in a series of three
workshop-based steering group meetings between February
2011 and 2012.
Discussions and workshops at the first meeting focused
on identifying the most critical goals, the unmet needs, and
areas for improvement/development in MS care.
At the second meeting, the group distilled the ‘‘areas for
development’’ identified at the first meeting into the highest
priority items, which would form the ‘‘overarching prin-
ciples’’ of the consensus statement. The mechanism for
choosing the highest priority items from the initial list of 12
was based on a voting system. Each member of the group
was asked to cast six votes to denote their highest priority
areas for development. The topics were placed on indi-
vidual posters and each member was given six red stickers
with which to indicate the areas that they considered to
present the greatest priority for development. Multiple
votes could be cast for a single topic if desired. No firm
limit was set as to the number of high-priority areas that
would be selected for final inclusion in the consensus
statement. Rather, the final items were decided through
group discussion.
Once the highest-priority items had been decided upon,
the group attempted to define the main points for each
principle in relation to the vision ‘‘Full access to person-
alized treatment, with reimbursement, to achieve freedom
from disease’’ in a workshop setting, and to identify what
should be done to realize these overarching principles.
The third steering group meeting consisted of a series of
discussions aimed at finding resolution on issues raised in
the previous meeting and ratifying the draft consensus
statement.
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Results
During the first meeting, 12 key areas for development
were identified by the group (Table 1).
During the second meeting, the voting process identified
which items the group felt were the highest priority topics
(Table 1). It was agreed that ‘‘early treatment’’ should be
included under the remit of ‘‘personalized care’’. There was
also general agreement that items ‘‘patient engagement’’ and
‘‘enabled patients’’ should be combined, with the revised
item termed ‘‘patient engagement and enablement’’. In
addition, a new category, ‘‘commitment to research’’, was
added to the list. The group agreed that seven ‘‘overarching
principles’’ should form the basis of the consensus state-
ment: personalized care, patient engagement, commitment
to research, regulatory body education and reimbursement
issues, new endpoints in clinical trials, more therapy options,
and MS centers of excellence.
The main points for each principle in relation to the
vision ‘‘Full access to personalized treatment, with reim-
bursement, to achieve freedom from disease’’ were out-
lined (Table 2) at the second meeting.
The consensus statement below represents the culmi-
nation of discussions at the three steering group meetings
and aims to present a strong vision for what the treatment
and care of MS should look like in the future.
Consensus statement
To realize our vision of full access to personalized treat-
ment, with reimbursement, to achieve freedom from
disease, we call upon healthcare providers and decision-
makers to address simultaneously the following overarch-
ing principles that will guide patient management, in order
to improve outcomes for people with MS.
Personalized care
We need personalized treatments for all types of MS [10,
11]. This means developing new approaches that incor-
porate a wide range of pharmacological and non-phar-
macological strategies that focus on the needs of people
living with the disease as individuals, and aim to reduce
disease activity, slow disability progression and improve
management of symptoms such as depression, immobil-
ity, fatigue, and others, which can be caused by MS
[10–12].
MS care requires diverse therapies and strategies to
address the complexity of the disease’s considerable
symptoms and challenges [13]. Governments, healthcare
decision-makers, and healthcare systems must be prepared
to see MS patients as requiring interventions beyond
greater access to disease-modifying agents alone, espe-
cially for those with progressive forms of MS.
The best treatment regimen is often specific to the
patient and best achieved through continuity of care with a
team of physicians and allied professionals [11, 12].
Healthcare decision-makers must realize that this outcome
is often compromised in modern hospitals, where, in the
name of efficiency, patients will generally see a sequence
of different doctors and may receive increasingly frag-
mented care. To overcome this barrier, we call on health-
care policy-makers to prioritize the development of centers
of excellence for improved access to personalized treat-
ment and to empower MS nurses as central coordinators for
patient care.
Patients also have the right to be informed about, and
involved in, all decisions regarding their treatment,
including early therapy options [11]. All available therapies
and their respective risks and benefits should be commu-
nicated to patients by their physicians, and patients should
also have access to other reliable, independent sources to
ensure that they are empowered to make informed deci-
sions [11, 14–16]. In addition, affording patients psycho-
logical and social support as part of their treatment package
is likely to ensure the greatest possible mitigation of the
potential financial, social, and psychosocial burdens asso-
ciated with MS [8, 12, 17–22].
Table 1 Number of votes received for each of the initial 12 ‘‘Areas
for development’’ in multiple sclerosis care as identified by the MS in
the 21st Century Steering Group
Area for development Number of votes (%);
n = 13, six votes
per person
Commitment to research 16 (20.5)
Regulatory body education 12 (15.4)
New endpoints in clinical trials 11 (14.1)
Healthcare and social care; personalized care 9 (11.5)
More therapy options 9 (11.5)
MS centers of excellence 7 (9)
Informed, shared decision-making 4 (5.1)
Better communication between stakeholders 3 (3.8)
Cost and reimbursement 3 (3.8)
Drugs with better risk:benefit profiles 2 (2.6)
Early treatment 1 (1.3)
Patient engagement and enablement 1 (1.3)
Each voting group member had a total of six votes. Multiple votes for
a single topic were allowed. The group that attended the second
meeting and were eligible to vote included eight neurologists, one
pharmacoepidemiologist/pharmacoeconomist, three MS group/soci-
ety members, and one consultant with a long-standing relationship
with the MS community in Canada
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Table 2 Feedback on defining the call for action
Areas for development Acknowledge
What are the current challenges?
Develop
What needs to be done to
achieve the vision for the 21st
Century?
Implement








Access to and engagement with
regulatory bodies
Burdensome regulations driving
expense and limiting innovation
(Industry, reducing loss)
Leading to costly and delayed
drugs
Different perceptions of risk
Opportunity cost
Resource cost, i.e., limited pool of
patients in trial centers























Reduced government funding for
basic research
A culture of research embedded
in all aspects of MS















No consensus currently on




Composite endpoints and scales
New types of clinical trials
Achieve consensus from expert
groups with endorsement of
regulatory authorities


















Fragmentation of care into
different departments








Empowerment of MS nurses
as central coordinators
MS centers of excellence
Patient engagement
Shared decision-making









More therapy options Cost/affordability
Safety
Tolerance
High level of regulatory demands
Relevance of placebo arm?
Long-term data on therapies
Standard approach to all kinds of
treatment
Decrease cost and increase
available resources
Cost-effectiveness strategies
Widen focus of research
Education and advocacy
Public support for longitudinal
patient registries
































Export and share positive
experiences
Open window for more
centers to participate in








EU European Union, MS multiple sclerosis
a Wording changed from ‘‘education’’ to ‘‘reform’’ in the breakout session
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Patient engagement
Patients should be engaged as advocates. They should be
empowered to drive negotiations with regulators and pay-
ers (see example below of how this has been achieved in
the field of HIV). In addition, patient organizations should
work more closely with clinicians, industry, and regulatory
bodies to petition for and secure research funds.
An example: How patient engagement has helped
improve outcomes for people with HIV
• Improvements in HIV treatment began when well-
organized patient groups started collaborations with
other stakeholders. This was during a period of
significant political and societal indifference.
• In 1983, the advisory committee of the People with
AIDS developed the ‘‘Denver Principles’’, which
empowered people with AIDS/HIV by changing how
they were viewed and treated.
• The organization ACT UP (the AIDS Coalition to
Unleash Power) who were committed to direct action to
end the AIDS crisis, made demands including better
access to drugs as well as cheaper prices, public
education about AIDS, and the prohibition of AIDS-
related discrimination.
• Other ways in which patient organizations have played
a role in improving outcomes in HIV:
• Treatment information and disease management
• Involvement in drug development and clinical trials
• Increased institutional involvement in regulatory
agencies
• Scientific societies
• Discussions with payers and Health Technology
Assessment (HTA) agencies
Learnings for MS care from the HIV initiative
• There are a similar number of patients with HIV and
MS in Europe (approximately 600,000–700,000). How-
ever, the awareness of MS in society is well below that
of HIV.
• A similar program to that adopted by the HIV
community, which motivates the broad MS community
to align behind a call to action and strongly challenges
the current treatment paradigm, would be beneficial.
Commitment to research
We need to embed a culture of research in all aspects of
MS care. The continued progress of basic research is cur-
rently under threat due to reduced charity income and
governmental funding. However, research across all
domains is key for a better understanding of disease
mechanisms, which ultimately leads to more effective new
treatment options (pharmacological and non-pharmaco-
logical), including therapies for progressive forms of MS.
We recommend the development of an international
network of MS centers of excellence (see below the MS
centers of excellence) as a platform for establishing
research networks and leveraging funding.
In addition, without compromising patient safety, we
call upon regulators to re-evaluate the existing European
Commission (EC) requirement for investigator-led
hypothesis-generating studies to meet the same standards
as industry-funded clinical trials, as this criterion has
severely limited the scope of such investigator-led studies.
Regulatory body education and reimbursement issues
The authors believe that patient groups, clinicians, and
industry need to have greater access to regulatory bodies at
a national and local level in order to:
• Improve the regulator’s understanding of the complex-
ities associated with the treatment and care of MS
patients
• Align perceptions of the risks of the disease and its
treatment.
The introduction of a conditional license, allowing
several thousand patients to be treated for a number of
years, would allow safety data to be formally gathered
from people with MS who are willing to take greater risks
and be exposed to greater uncertainty.
Regulatory bodies need to consider how escalating
regulatory requirements, including increasing demands for
long-term safety data, could be major drivers for spiraling
development costs [23–25]. This leads to increasing drug
prices, limited innovation, and delays in getting promising
drugs to patients.
Reimbursement agencies should consider the substantial
indirect costs associated with MS [3, 26–37] and the related
burden to society in their calculation of cost:benefit ratios.
New endpoints in clinical trials
Clinical trials in MS are still largely based on single-
parameter measures of disease relapses or disability pro-
gression [38]. Other parameters, such as subclinical
inflammatory activity, neuroprotection, lesion burden
detected by MRI, health economics, cognitive impairment,
and fatigue are regarded only as secondary endpoints or are
rarely measured at all. Employing the use of single-
parameter measures in clinical trials can fail to measure the
effect of treatment on the actual disease process, and these
strategies only partly reflect real-world treatment scenarios.
Developing better patient- and physician-reported tools are
466 J Neurol (2013) 260:462–469
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needed for the assessment of these parameters, and using
those within composite endpoints may, therefore, improve
measures of treatment efficacy. In fact, a number of groups
have recently used composite endpoints in phase 3 clinical
trials with success [39–44].
New clinical trial designs and endpoints that enable
effective treatment development and evaluation to achieve
relevant benefits are needed [38]. Such endpoints should
include patient-reported measures, clinical and functional
assessments, and biomarkers [45–47]. We encourage the
development of initiatives involving regulatory authorities,
expert groups, and industry, which will amalgamate these
disparate elements into new composite endpoints/scales [45].
More therapy options
Although there are already multiple pharmacological
treatment options available for MS, the high costs of these
treatments may limit patient access [48]. Governments,
regulators, funding agencies, clinicians, the pharmaceutical
industry, and patient groups need to work together to
develop strategies to deliver more cost-effective medicines.
They also need to widen the focus of research to ensure the
continuous development of better therapy options with
improved efficacy, safety, and tolerability profiles.
Patients should have greater access to comprehensive
care regimens that include symptomatic care, rehabilita-
tion, and psychological support alongside pharmacological
solutions [11].
Non-responding patients and those with aggressive dis-
ease should be allowed access to experimental treatment
options in well-controlled programs. We petition regula-
tory bodies and funders to provide this access. In addition,
we ask regulators and funders to consider the relevance of
the placebo arm and the assimilation of more long-term
data on the therapy options available. In this regard, we
support the European Commission’s consideration for a
patient registry [4].
MS centers of excellence
We need a network of dedicated MS centers of excellence
that meet a set of predetermined minimum standards and
demonstrate a will to contribute to research and to share
resources. This is to improve diagnosis and treatment, as
well as to provide optimum patient support [12].
Potential benefits of the consensus statement on future
MS care
This statement is intended to raise awareness of future MS
care and has the overall aim of affording MS patients
freedom from disease. Initiatives that disseminate
information about potential gaps in care identified by MS
experts may give rise to adoption of practices that promote
improved future care of MS. Should the elements of this
consensus statement be integrated into MS care, we foresee
the following benefits:
• Ensure patients fully understand their treatment options
• Ensure healthcare decision-makers understand the
complexities of MS and the degree to which patients
are willing to accept risks of therapies
• Overcome the stigma associated with MS to achieve
better social integration of people with MS
• Develop strategies to improve the cost-effectiveness of
MS medicines
• Ensure patients have access to more treatment options
• Improve communication between clinicians, regulatory
authorities, and healthcare bodies.
Discussion
The steering group of the ‘‘MS in the 21st Century’’ ini-
tiative believes that it is the right of every patient to have
access to early diagnosis, more and better treatment
options, rehabilitation and regeneration strategies, and
effective management of MS symptoms.
This publication is a call to all regulators, healthcare
providers and decision-makers, clinicians, industry repre-
sentatives, and patient groups within the MS community to
work together to ensure that all people affected by MS have
full access to personalized treatment, with reimbursement.
Our vision is for people affected by MS to have freedom
from disease.
The steering group acknowledges that for this initiative
to be successful it will be imperative to engage appropriate
stakeholders, including regulators and patients, and
develop a strong collaboration with them to ensure that the
principles underlying the statement are accomplished.
Members of the steering group are currently seeking
endorsement of the consensus statement from individuals,
as well as professional and patient organizations. The
highest priority groups with which to engage were identi-
fied as specific agencies, national MS and neurological
societies, academic groups, and patient organizations.
Limitations
One limitation of this consensus statement is that it is based
primarily on the opinions of experts who agreed to par-
ticipate in the MS in the 21st Century initiative. As such, it
will naturally be skewed to the personal opinions of those
attending (a large proportion of who were neurologists).
J Neurol (2013) 260:462–469 467
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However, the group has attempted to overcome this, in
part, by further disseminating the consensus statement to
other bodies, requesting their endorsement and further
comments.
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